Viral Hepatitis C New Microelimination Pathways Objective: Psychiatric Communities HCV Free
- PMID: 36431008
- PMCID: PMC9697639
- DOI: 10.3390/life12111873
Viral Hepatitis C New Microelimination Pathways Objective: Psychiatric Communities HCV Free
Abstract
Background: People with psychiatric disorders have a high prevalence of HCV. For this reason, tailored interventions should be developed to reach this population.
Methods: We performed a retrospective study on patients treated for HCV infection in psychiatric nursing homes, approached with a quick diagnosis, staging and treatment.
Results: We included data on 586 people screened for HCV with quick tests. High HCV seroprevalence was found in this population (231; 39.4%). Among people who tested positive, there were high rates of active infection (220; 95.2%). Out of the 220 patients with active infection, 95.9% were male, 85.5% were Italian, median age was 43 (IQR = 35-52) years old. In the majority of cases (162; 73.6%), the risk factor was unknown. The most common genotype was 3a (98; 44.5%), and patients mostly had a low fibrosis, according with FIB-4 value (142; 64.5%). Of them, one (0.45%) categorically refused the treatment, and one (0.45%) had liver cirrhosis and advanced hepatocellular carcinoma. Overall, 218 patients underwent eligibility for DAAs. The most prescribed treatment was glecaprevir/pibrentasvir (GLE/PIB (172; 78.2%)). The others practiced sofosbuvir/velpatasvir (SOF/VEL). All patients reached the end of treatment. One (0.45%) was lost to follow up, and all the others reached the SVR12.
Conclusions: The point-of-care testing and pangenotypic DAAs' availability represent one of the most important steps for a fast diagnostic and therapeutical option. Tailored microelimination pathways for every difficult-to-reach/to-treat populations are needed. This would allow us to move more easily towards HCV elimination.
Keywords: DAAs; chronic HCV hepatitis; microelimination programs; psychiatric disorders.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.Eur J Hosp Pharm. 2020 Mar;27(e1):e41-e47. doi: 10.1136/ejhpharm-2019-002060. Epub 2020 Feb 7. Eur J Hosp Pharm. 2020. PMID: 32296504 Free PMC article.
-
Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.J Gastroenterol Hepatol. 2021 Oct;36(10):2911-2916. doi: 10.1111/jgh.15546. Epub 2021 May 19. J Gastroenterol Hepatol. 2021. PMID: 33978973
-
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.Liver Int. 2020 Apr;40(4):769-777. doi: 10.1111/liv.14386. Epub 2020 Feb 3. Liver Int. 2020. PMID: 31970845
-
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.J Viral Hepat. 2020 Aug;27(8):762-769. doi: 10.1111/jvh.13317. Epub 2020 May 25. J Viral Hepat. 2020. PMID: 32386099 Review.
-
A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.Expert Opin Pharmacother. 2017 Apr;18(5):535-543. doi: 10.1080/14656566.2017.1282459. Epub 2017 Mar 24. Expert Opin Pharmacother. 2017. PMID: 28092171 Review.
Cited by
-
Women Living with HIV in Italian Prison Settings: Results from the Gender-Specific ROSE Network.Viruses. 2023 Feb 10;15(2):497. doi: 10.3390/v15020497. Viruses. 2023. PMID: 36851711 Free PMC article.
-
Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.World J Gastroenterol. 2023 Jul 7;29(25):4085-4098. doi: 10.3748/wjg.v29.i25.4085. World J Gastroenterol. 2023. PMID: 37476581 Free PMC article.
-
Facing HCV as a Major Public Healthcare Threat in Italy: Epidemiology and Micro-Elimination Pathways among Underserved Populations.Healthcare (Basel). 2023 Jul 24;11(14):2109. doi: 10.3390/healthcare11142109. Healthcare (Basel). 2023. PMID: 37510549 Free PMC article. Review.
References
-
- WHO Hepatitis C factsheets. Switzerland. 2022. [(accessed on 29 September 2022)]. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
LinkOut - more resources
Full Text Sources